Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    ISSN: 1432-2072
    Keywords: Yohimbine ; Noradrenergic ; Anxiety PTSD
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Preclinical and clinical studies have suggested that the acoustic startle reflex (ASR) is a useful model to investigate the neurochemical basis of anxiety and fear states. This work has revealed that the anxiogenic alpha-2 receptor antagonist, yohimbine, increases the amplitude of the ASR in laboratory animals and in healthy human controls. Because of the growing body of data that support the hypothesis that severe stress results in substantial alterations in noradrenergic neuronal reactivity, the present investigation evaluated the effects of yohimbine on the ASR of 18 patients with PTSD and 11 healthy combat controls. Subjects received IV yohimbine (0.4 mg/kg) or saline placebo on 2 separate days in a randomized double blind placebo control design. A trial of two tone frequencies with varied intensity (90, 96, 102, 108, 114 dB) white noise and instantaneous rise time, was delivered binaurally through headphones. Tones were delivered every 25–60 s, for a 40-ms duration. Startle testing was performed 80 min post-infusion and lasted 15–20 min. Yohimbine significantly increased the amplitude, magnitude and probability of the ASR in combat veterans with PTSD, but did not do so in combat controls. Overall startle was significantly larger in the PTSD subjects; however, this did not account for the differential effect of yohimbine, since yohimbine had no significant effect in the control group. This study demonstrates an excitatory effect of yohimbine on the amplitude, magnitude and probability of the ASR in PTSD patients that is not seen in combat controls. In the context of the key role of this reflex in the alarm response, this finding adds to the array of documented behavioral, biochemical and cardiovascular effects of yohimbine in humans which support the relationship between increased noradrenergic function and exaggerated startle symptomatology of PTSD.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    Electronic Resource
    Electronic Resource
    Springer
    Archives of toxicology 25 (1969), S. 229-237 
    ISSN: 1432-0738
    Keywords: Sultiamum (Ospolot) ; Anticonvulsant ; Suicide ; Analysis ; Distribution in Organism ; Sultiamum (Ospolot) ; Antikonvulsivum ; Suicid ; Analytik ; Verteilung im Organismus
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Eine 24jährige Epileptikerin kam 1 Tag nach Einnahme einer hohen Überdosis Ospolot (Sultiamum) ad exitum. Die am 4. Tag post mortem durchgeführte Leichenöffnung sowie die feingeweblichen Untersuchungen ließen keine spezifischen Schädigungen erkennen. Chemisch-analytische Untersuchungen ergaben auffallend hohe Konzentrationen unveränderter Wirksubstanz (um 350 ppm) in den Körperflüssigkeiten und Organen. Es wurde eine einfache und empfindliche Verfahrensweise zur schnellen Bestimmung des Wirkstoffes an frischen, gelagerten und formaldehydhaltigen Organmaterialien entwickelt.
    Notes: Summary A 24 year old female died one day after taking a large overdose of Ospolot (Sultiamum). The autopsy which was performed on the 4th postmortum day and histological tissue studies demonstrated no specific lesions. Chemical analysis showed markedly high concentrations of the unaltered substance (about 350 ppm) in body fluids and organs. A simple and sensitive method for rapid qualitative and quantitative determination of Sultiamum in fresh, stored and formaldehyde-containing biological materials was developed.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...